Ravi Rasendra Mazumdar
Director/Board Member at BIOCON LIMITED
Net worth: 17 M $ as of 2024-03-30
Ravi Rasendra Mazumdar active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BIOCON LIMITED | Director/Board Member | 1999-12-31 | - |
| The University of Waterloo | Corporate Officer/Principal | 2011-09-05 | - |
| Indian Institute of Science | Corporate Officer/Principal | 2011-09-05 | - |
| Glentec International | Director/Board Member | 2011-09-05 | - |
Biocon Biologics Uk Ltd.
 Biocon Biologics Uk Ltd. Miscellaneous Commercial ServicesCommercial Services Biocon Biologics UK Ltd. is a biopharmaceutical company founded in 2016. The private company is based in London, UK. The British company is focused on finding new and affordable ways to treat diabetes, cancer, and autoimmune diseases. Biocon develops affordable biosimilars, generic formulations, and complex APIs. The company's work in novel biologics and novel targets in large molecules has significant results in diabetes, oncology, and immunology. The company provides access to share information, news, press releases, company statements, media stories, factsheet, leadership profile, reports, video, and image gallery. Syngene, a division of Biocon, is divided into four divisions - drug discovery services, drug development services, manufacturing services, and dedicated R&D centers. | Director/Board Member | 2021-01-18 | - |
Career history of Ravi Rasendra Mazumdar
Former positions of Ravi Rasendra Mazumdar
| Companies | Position | Start | End |
|---|---|---|---|
| INRS University | Corporate Officer/Principal | - | - |
| The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | - | - |
| University of Essex | Corporate Officer/Principal | - | - |
| Purdue University | Corporate Officer/Principal | - | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░ ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Ravi Rasendra Mazumdar
| Imperial College London | Graduate Degree |
| University of California, Los Angeles | Doctorate Degree |
| Indian Institute of Technology Bombay | Undergraduate Degree |
Statistics
International
| United States | 6 |
| United Kingdom | 4 |
| Canada | 4 |
Operational
| Corporate Officer/Principal | 9 |
| Director/Board Member | 4 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 11 |
| Technology Services | 3 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 6 |
|---|---|
Macrovision Corp.
 Macrovision Corp. Information Technology ServicesTechnology Services Macrovision Corp., provides software and entertainment technology services. It provides services to content owners, software and hardware vendors. It was founded in the year 1983. The company headquaters is located at California. | Technology Services |
98th Street Ventures, Inc.
 98th Street Ventures, Inc. Packaged SoftwareTechnology Services 98th Street Ventures, Inc. develops software for mobile Internet devices. The company was founded by Frank A. O'Donnell, Roger P.Hickey and Paul J. Duggan in 2003 and is headquartered in Evergreen Park, IL. | Technology Services |
| Biocon Ltd. | |
| Glentec International | |
Clinigene International Ltd.
 Clinigene International Ltd. Medical/Nursing ServicesHealth Services Clinigene International Ltd. provided clinical research services. The company is headquartered in Bangalore, India. | Health Services |
Biocon Biologics Uk Ltd.
Biocon Biologics Uk Ltd. Miscellaneous Commercial ServicesCommercial Services Biocon Biologics UK Ltd. is a biopharmaceutical company founded in 2016. The private company is based in London, UK. The British company is focused on finding new and affordable ways to treat diabetes, cancer, and autoimmune diseases. Biocon develops affordable biosimilars, generic formulations, and complex APIs. The company's work in novel biologics and novel targets in large molecules has significant results in diabetes, oncology, and immunology. The company provides access to share information, news, press releases, company statements, media stories, factsheet, leadership profile, reports, video, and image gallery. Syngene, a division of Biocon, is divided into four divisions - drug discovery services, drug development services, manufacturing services, and dedicated R&D centers. | Commercial Services |